Botanix Pharmaceuticals (ASX:BOT) targeting skin disease

0
146



Botanix Pharmaceuticals Limited (ASX:BOT) President, Vince Ippolito, talks about interim results from the company’s BTX 1308 psoriasis phase 1b study and opportunities in global medical dermatology.

SHARE
Previous article‘Broken system’ starves U.S. oil boom of immigrant workers
Next articleChinese Vice Premier Liu He says China brings sincerity to trade talks